Cargando…

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D(2)/D(3) Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants

Gastroparesis is a chronic neuromuscular disorder of the upper gastrointestinal tract in which episodic exacerbation can lead to frequent hospitalizations and severe disability. Dopamine D(2)/D(3) receptor antagonists have been used to treat patients with gastroparesis with some efficacy; however, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whiting, Roger L., Darpo, Borje, Chen, Chunlin, Fletcher, Margaret, Combs, Dan, Xue, Hongqi, Stoltz, Randall R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451790/ https://www.ncbi.nlm.nih.gov/pubmed/33462988 http://dx.doi.org/10.1002/cpdd.906

Ejemplares similares

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022)

Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D(2)/D(3) Selective Receptor Antagonist for the Management of Gastroparesis
por: Kreckler, Laura, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D(2)/D(3) Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
por: Chen, Chunlin, et al.
Publicado: (2021)

The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study
por: Mukker, Jatinder K., et al.
Publicado: (2022)

Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D(2)/D(3) Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants
por: Yamaguchi, Takayoshi, et al.
Publicado: (2021)

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
por: Borin, Marie T., et al.
Publicado: (2019)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019)

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
por: Hoch, Matthias, et al.
Publicado: (2014)

Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals
por: Darpo, Borje, et al.
Publicado: (2017)

Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
por: Lam, Wing, et al.
Publicado: (2018)

A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers
por: Hossain, Mohammad, et al.
Publicado: (2017)

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
por: Mueller, Markus S., et al.
Publicado: (2020)

The New S7B/E14 Question and Answer Draft Guidance for Industry: Contents and Commentary
por: Darpo, Borje, et al.
Publicado: (2021)

Fantasia in C minor, BWV906 Fifteen two-part inventions ; Fifteen three-part sinfonias (inventions) ; Chromatic fantasia and fugue : in D minor, BWV903 /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1994)

Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
por: Martin, Patrick, et al.
Publicado: (2020)

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis
por: Schneider, Frank, et al.
Publicado: (2022)

Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
por: Yoneyama, Tomoki, et al.
Publicado: (2020)

Carpal Tunnel Syndrome: The Role of Occupational Factors Among 906 Workers
por: Ghasemi, Mohammad, et al.
Publicado: (2012)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

906 How Mandatory Public Reporting Undermines Infection Prevention: An Ethnographic Study
por: Szymczak, Julia E., et al.
Publicado: (2014)

SUN-906 To Function or Not to Function: A Rare Case of Metachronous Hormone Syndrome
por: Amine, Adele, et al.
Publicado: (2020)

CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK–779
por: Nedjai, Belinda, et al.
Publicado: (2015)

TAK-242 ameliorates contact dermatitis exacerbated by IL-36 receptor antagonist deficiency
por: Fukushima, Hidehiko, et al.
Publicado: (2020)

No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
por: Mu, Song, et al.
Publicado: (2020)

Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data
por: Hassing, Gerardus J., et al.
Publicado: (2022)

Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906)
por: Scherzinger-Laude, Karine, et al.
Publicado: (2013)

MON-906 MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A: Familiar Case Report
por: Sousa, Barbara K P, et al.
Publicado: (2020)

The Toll-like receptor 4 antagonist TAK-242 protects against chronic pancreatitis in rats
por: Pan, Long-Fei, et al.
Publicado: (2017)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A
por: Yin, Wei, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Pharmacodynamics of the Glutamate Receptor Antagonists in the Rat Barrel Cortex
por: Vinokurova, Daria, et al.
Publicado: (2018)

Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
por: Koblin, B, et al.
Publicado: (2012)

Operación y mantenimiento de la impresora MT 906 con proceso electrofotográfico láser /
por: Pérez Ramírez, Ángela
Publicado: (1994)

Development and Characterization of 1,906 EST-SSR Markers from Unigenes in Jute (Corchorus spp.)
por: Zhang, Liwu, et al.
Publicado: (2015)

The Significant Pathways and Genes Underlying the Colon Cancer Treatment by the Traditional Chinese Medicine PHY906
por: Su, Ziyuan, et al.
Publicado: (2017)

906. Surgical Site Infections in Children with Beta-Lactam Allergy: A Matched Cohort Study
por: Huang, Felicia Scaggs, et al.
Publicado: (2020)

A Feedback Regulatory Loop Involving dTrbd/dTak1 in Controlling IMD Signaling in Drosophila Melanogaster
por: Hua, Yongzhi, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_aim8ts1l119kj11i3jg0n9c4r4